ID   APOA5_HUMAN             Reviewed;         366 AA.
AC   Q6Q788; B0YIV9; Q3MIK6; Q6UWK9; Q9UBJ3;
DT   01-FEB-2005, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   12-APR-2017, entry version 129.
DE   RecName: Full=Apolipoprotein A-V;
DE            Short=Apo-AV;
DE            Short=ApoA-V;
DE   AltName: Full=Apolipoprotein A5;
DE   AltName: Full=Regeneration-associated protein 3;
DE   Flags: Precursor;
GN   Name=APOA5; Synonyms=RAP3; ORFNames=UNQ411/PRO773;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=11577099; DOI=10.1074/jbc.M106888200;
RA   van Der Vliet H.N., Sammels M.G., Leegwater A.C.J., Levels J.H.M.,
RA   Reitsma P.H., Boers W., Chamuleau R.A.F.M.;
RT   "Apolipoprotein A-V. A novel apolipoprotein associated with an early
RT   phase of liver regeneration.";
RL   J. Biol. Chem. 276:44512-44520(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TRP-19 AND MET-153.
RX   PubMed=15108119; DOI=10.1007/s00439-004-1106-x;
RA   Fullerton S.M., Buchanan A.V., Sonpar V.A., Taylor S.L., Smith J.D.,
RA   Carlson C.S., Salomaa V., Stengaard J.H., Boerwinkle E., Clark A.G.,
RA   Nickerson D.A., Weiss K.M.;
RT   "The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.";
RL   Hum. Genet. 115:36-56(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=11588264; DOI=10.1126/science.1064852;
RA   Pennacchio L.A., Olivier M., Hubacek J.A., Cohen J.C., Cox D.R.,
RA   Fruchart J.-C., Krauss R.M., Rubin E.M.;
RT   "An apolipoprotein influencing triglycerides in humans and mice
RT   revealed by comparative sequencing.";
RL   Science 294:169-173(2001).
RN   [7]
RP   FUNCTION.
RX   PubMed=12899628; DOI=10.1021/bi034509t;
RA   Beckstead J.A., Oda M.N., Martin D.D.O., Forte T.M., Bielicki J.K.,
RA   Berger T., Luty R., Kay C.M., Ryan R.O.;
RT   "Structure-function studies of human apolipoprotein A-V: a regulator
RT   of plasma lipid homeostasis.";
RL   Biochemistry 42:9416-9423(2003).
RN   [8]
RP   INDUCTION.
RX   PubMed=12709436; DOI=10.1074/jbc.M301302200;
RA   Prieur X., Coste H., Rodriguez J.C.;
RT   "The human apolipoprotein AV gene is regulated by peroxisome
RT   proliferator-activated receptor-alpha and contains a novel farnesoid
RT   X-activated receptor response element.";
RL   J. Biol. Chem. 278:25468-25480(2003).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12810715; DOI=10.1074/jbc.M303784200;
RA   Weinberg R.B., Cook V.R., Beckstead J.A., Martin D.D.O.,
RA   Gallagher J.W., Shelness G.S., Ryan R.O.;
RT   "Structure and interfacial properties of human apolipoprotein A-V.";
RL   J. Biol. Chem. 278:34438-34444(2003).
RN   [10]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15528295; DOI=10.1373/clinchem.2004.040824;
RA   O'Brien P.J., Alborn W.E., Sloan J.H., Ulmer M., Boodhoo A.,
RA   Knierman M.D., Schultze A.E., Konrad R.J.;
RT   "The novel apolipoprotein A5 is present in human serum, is associated
RT   with VLDL, HDL, and chylomicrons, and circulates at very low
RT   concentrations compared with other apolipoproteins.";
RL   Clin. Chem. 51:351-359(2005).
RN   [11]
RP   INTERACTION WITH GPIHBP1.
RX   PubMed=17997385; DOI=10.1016/j.bbalip.2007.10.005;
RA   Gin P., Beigneux A.P., Davies B., Young M.F., Ryan R.O., Bensadoun A.,
RA   Fong L.G., Young S.G.;
RT   "Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to
RT   GPIHBP1 containing a G56R amino acid substitution.";
RL   Biochim. Biophys. Acta 1771:1464-1468(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-59, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   PHOSPHORYLATION AT THR-55.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [14]
RP   POLYMORPHISM, AND VARIANT TRP-19.
RX   PubMed=12417524; DOI=10.1093/hmg/11.24.3031;
RA   Pennacchio L.A., Olivier M., Hubacek J.A., Krauss R.M., Rubin E.M.,
RA   Cohen J.C.;
RT   "Two independent apolipoprotein A5 haplotypes influence human plasma
RT   triglyceride levels.";
RL   Hum. Mol. Genet. 11:3031-3038(2002).
RN   [15]
RP   VARIANT TRP-19.
RX   PubMed=12920097; DOI=10.1136/jmg.40.8.e105;
RA   Vrablik M., Horinek A., Ceska R., Adamkova V., Poledne R.,
RA   Hubacek J.A.;
RT   "Ser19Trp polymorphism within the apolipoprotein AV gene in
RT   hypertriglyceridaemic people.";
RL   J. Med. Genet. 40:E105-E105(2003).
RN   [16]
RP   VARIANT CYS-185.
RX   PubMed=12915450; DOI=10.1093/hmg/ddg255;
RA   Kao J.-T., Wen H.-C., Chien K.-L., Hsu H.-C., Lin S.-W.;
RT   "A novel genetic variant in the apolipoprotein A5 gene is associated
RT   with hypertriglyceridemia.";
RL   Hum. Mol. Genet. 12:2533-2539(2003).
RN   [17]
RP   INVOLVEMENT IN HLPP5.
RX   PubMed=16200213; DOI=10.1172/JCI24471;
RA   Marcais C., Verges B., Charriere S., Pruneta V., Merlin M., Billon S.,
RA   Perrot L., Drai J., Sassolas A., Pennacchio L.A., Fruchart-Najib J.,
RA   Fruchart J.C., Durlach V., Moulin P.;
RT   "Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia
RT   due to lipoprotein lipase impairment.";
RL   J. Clin. Invest. 115:2862-2869(2005).
CC   -!- FUNCTION: Minor apolipoprotein mainly associated with HDL and to a
CC       lesser extent with VLDL. May also be associated with chylomicrons.
CC       Important determinant of plasma triglyceride (TG) levels by both
CC       being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG
CC       hydrolysis and a inhibitor of the hepatic VLDL-TG production rate
CC       (without affecting the VLDL-apoB production rate) (By similarity).
CC       Activates poorly lecithin:cholesterol acyltransferase (LCAT) and
CC       does not enhance efflux of cholesterol from macrophages.
CC       {ECO:0000250, ECO:0000269|PubMed:11588264,
CC       ECO:0000269|PubMed:12899628, ECO:0000269|PubMed:15528295}.
CC   -!- SUBUNIT: Interacts with GPIHBP1. {ECO:0000269|PubMed:17997385}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:12810715}.
CC   -!- TISSUE SPECIFICITY: Liver and plasma.
CC       {ECO:0000269|PubMed:11577099, ECO:0000269|PubMed:11588264,
CC       ECO:0000269|PubMed:15528295}.
CC   -!- INDUCTION: Up-regulated by PPARA agonists, which are used
CC       clinically to lower serum TG (such as fibrates).
CC       {ECO:0000269|PubMed:12709436}.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- POLYMORPHISM: Three common alleles are known: allele APOA5*1,
CC       APOA5*2 and APOA5*3. The APOA5*2 haplotype, which consists of 3
CC       non-coding SNPs, is present in approximately 16% of Caucasians and
CC       is associated with increased plasma triglyceride concentrations.
CC       APOA5*3 haplotype is defined by the rare Ser-19-Trp substitution.
CC       Together, the APOA5*2 and APOA5*3 haplotypes are found in 25 to
CC       50% of African Americans, Hispanics, and Caucasians.
CC       {ECO:0000269|PubMed:12417524}.
CC   -!- DISEASE: Hypertriglyceridemia, familial (FHTR) [MIM:145750]: A
CC       common inherited disorder in which the concentration of very low
CC       density lipoprotein (VLDL) is elevated in the plasma. This leads
CC       to increased risk of heart disease, obesity, and pancreatitis.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Hyperlipoproteinemia 5 (HLPP5) [MIM:144650]:
CC       Characterized by increased amounts of chylomicrons and very low
CC       density lipoprotein (VLDL) and decreased low density lipoprotein
CC       (LDL) and high density lipoprotein (HDL) in the plasma after a
CC       fast. Numerous conditions cause this phenotype, including insulin-
CC       dependent diabetes mellitus, contraceptive steroids, alcohol
CC       abuse, and glycogen storage disease type 1A (GSD1A).
CC       {ECO:0000269|PubMed:16200213}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Induced in early phase of liver regeneration.
CC   -!- SIMILARITY: Belongs to the apolipoprotein A1/A4/E family.
CC       {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-4 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF25661.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF25662.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAQ89109.1; Type=Erroneous termination; Positions=275; Note=Translated as Gln.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF202889; AAF25661.1; ALT_INIT; mRNA.
DR   EMBL; AF202890; AAF25662.1; ALT_INIT; mRNA.
DR   EMBL; AY555191; AAS68229.1; -; Genomic_DNA.
DR   EMBL; AY422949; AAQ91808.1; -; Genomic_DNA.
DR   EMBL; AY358749; AAQ89109.1; ALT_SEQ; mRNA.
DR   EMBL; EF444949; ACA05937.1; -; Genomic_DNA.
DR   EMBL; EF444949; ACA05938.1; -; Genomic_DNA.
DR   EMBL; BC101787; AAI01788.1; -; mRNA.
DR   EMBL; BC101789; AAI01790.1; -; mRNA.
DR   CCDS; CCDS8376.2; -.
DR   RefSeq; NP_001160070.1; NM_001166598.1.
DR   RefSeq; NP_443200.2; NM_052968.4.
DR   RefSeq; XP_016872658.1; XM_017017169.1.
DR   UniGene; Hs.283923; -.
DR   ProteinModelPortal; Q6Q788; -.
DR   SMR; Q6Q788; -.
DR   BioGrid; 125518; 3.
DR   IntAct; Q6Q788; 10.
DR   STRING; 9606.ENSP00000227665; -.
DR   iPTMnet; Q6Q788; -.
DR   PhosphoSitePlus; Q6Q788; -.
DR   BioMuta; APOA5; -.
DR   DMDM; 60391728; -.
DR   MaxQB; Q6Q788; -.
DR   PaxDb; Q6Q788; -.
DR   PeptideAtlas; Q6Q788; -.
DR   PRIDE; Q6Q788; -.
DR   Ensembl; ENST00000227665; ENSP00000227665; ENSG00000110243.
DR   Ensembl; ENST00000542499; ENSP00000445002; ENSG00000110243.
DR   GeneID; 116519; -.
DR   KEGG; hsa:116519; -.
DR   UCSC; uc001ppr.4; human.
DR   CTD; 116519; -.
DR   DisGeNET; 116519; -.
DR   GeneCards; APOA5; -.
DR   HGNC; HGNC:17288; APOA5.
DR   MalaCards; APOA5; -.
DR   MIM; 144650; phenotype.
DR   MIM; 145750; phenotype.
DR   MIM; 606368; gene.
DR   neXtProt; NX_Q6Q788; -.
DR   OpenTargets; ENSG00000110243; -.
DR   Orphanet; 413; Hyperlipoproteinemia type 4.
DR   Orphanet; 70470; Hyperlipoproteinemia type 5.
DR   PharmGKB; PA24888; -.
DR   eggNOG; ENOG410IKFF; Eukaryota.
DR   eggNOG; ENOG410YHUG; LUCA.
DR   GeneTree; ENSGT00810000125596; -.
DR   HOGENOM; HOG000253942; -.
DR   HOVERGEN; HBG050545; -.
DR   InParanoid; Q6Q788; -.
DR   KO; K09025; -.
DR   OMA; HRSVAPH; -.
DR   OrthoDB; EOG091G0IA5; -.
DR   PhylomeDB; Q6Q788; -.
DR   TreeFam; TF334458; -.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   SIGNOR; Q6Q788; -.
DR   GeneWiki; APOA5; -.
DR   GenomeRNAi; 116519; -.
DR   PRO; PR:Q6Q788; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000110243; -.
DR   CleanEx; HS_APOA5; -.
DR   ExpressionAtlas; Q6Q788; baseline and differential.
DR   Genevisible; Q6Q788; HS.
DR   GO; GO:0072562; C:blood microparticle; IBA:GO_Central.
DR   GO; GO:0042627; C:chylomicron; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0015485; F:cholesterol binding; IBA:GO_Central.
DR   GO; GO:0017127; F:cholesterol transporter activity; IBA:GO_Central.
DR   GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IDA:BHF-UCL.
DR   GO; GO:0008201; F:heparin binding; IDA:BHF-UCL.
DR   GO; GO:0060229; F:lipase activator activity; IMP:BHF-UCL.
DR   GO; GO:0035473; F:lipase binding; IPI:BHF-UCL.
DR   GO; GO:0008289; F:lipid binding; IDA:UniProtKB.
DR   GO; GO:0060230; F:lipoprotein lipase activator activity; IDA:BHF-UCL.
DR   GO; GO:0070325; F:lipoprotein particle receptor binding; IPI:BHF-UCL.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; IPI:BHF-UCL.
DR   GO; GO:0031210; F:phosphatidylcholine binding; IDA:BHF-UCL.
DR   GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; IBA:GO_Central.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0055090; P:acylglycerol homeostasis; IDA:BHF-UCL.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IBA:GO_Central.
DR   GO; GO:0033344; P:cholesterol efflux; IBA:GO_Central.
DR   GO; GO:0042632; P:cholesterol homeostasis; IDA:BHF-UCL.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; IBA:GO_Central.
DR   GO; GO:0006869; P:lipid transport; IDA:BHF-UCL.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IBA:GO_Central.
DR   GO; GO:0031102; P:neuron projection regeneration; IBA:GO_Central.
DR   GO; GO:0046470; P:phosphatidylcholine metabolic process; IBA:GO_Central.
DR   GO; GO:0033700; P:phospholipid efflux; IBA:GO_Central.
DR   GO; GO:0010873; P:positive regulation of cholesterol esterification; IBA:GO_Central.
DR   GO; GO:0045723; P:positive regulation of fatty acid biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0050996; P:positive regulation of lipid catabolic process; IDA:BHF-UCL.
DR   GO; GO:0051006; P:positive regulation of lipoprotein lipase activity; IDA:BHF-UCL.
DR   GO; GO:0048260; P:positive regulation of receptor-mediated endocytosis; TAS:BHF-UCL.
DR   GO; GO:0010898; P:positive regulation of triglyceride catabolic process; IDA:BHF-UCL.
DR   GO; GO:0010902; P:positive regulation of very-low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0030300; P:regulation of intestinal cholesterol absorption; IBA:GO_Central.
DR   GO; GO:0043691; P:reverse cholesterol transport; IBA:GO_Central.
DR   GO; GO:0042246; P:tissue regeneration; IEP:UniProtKB.
DR   GO; GO:0019433; P:triglyceride catabolic process; IMP:BHF-UCL.
DR   GO; GO:0070328; P:triglyceride homeostasis; IDA:BHF-UCL.
DR   GO; GO:0006641; P:triglyceride metabolic process; IDA:BHF-UCL.
DR   GO; GO:0034370; P:triglyceride-rich lipoprotein particle remodeling; IEA:Ensembl.
DR   InterPro; IPR000074; ApoA_E.
DR   Pfam; PF01442; Apolipoprotein; 2.
PE   1: Evidence at protein level;
KW   Chylomicron; Coiled coil; Complete proteome; Disease mutation; HDL;
KW   Lipid transport; Phosphoprotein; Polymorphism; Reference proteome;
KW   Secreted; Signal; Transport; VLDL.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    366       Apolipoprotein A-V.
FT                                /FTId=PRO_0000001981.
FT   COILED       54    157       {ECO:0000255}.
FT   COILED      236    262       {ECO:0000255}.
FT   MOD_RES      55     55       Phosphothreonine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES      59     59       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VARIANT      19     19       S -> W (in allele APOA5*3; associated
FT                                with high plasma triglyceride levels;
FT                                dbSNP:rs3135506).
FT                                {ECO:0000269|PubMed:12417524,
FT                                ECO:0000269|PubMed:12920097,
FT                                ECO:0000269|PubMed:15108119}.
FT                                /FTId=VAR_021165.
FT   VARIANT      37     37       D -> E (in dbSNP:rs34282181).
FT                                /FTId=VAR_035124.
FT   VARIANT     153    153       V -> M (in dbSNP:rs3135507).
FT                                {ECO:0000269|PubMed:15108119}.
FT                                /FTId=VAR_021166.
FT   VARIANT     185    185       G -> C (associated with high plasma
FT                                triglyceride levels; dbSNP:rs2075291).
FT                                {ECO:0000269|PubMed:12915450}.
FT                                /FTId=VAR_021167.
SQ   SEQUENCE   366 AA;  41213 MW;  A1C9C207024D0DAF CRC64;
     MASMAAVLTW ALALLSAFSA TQARKGFWDY FSQTSGDKGR VEQIHQQKMA REPATLKDSL
     EQDLNNMNKF LEKLRPLSGS EAPRLPQDPV GMRRQLQEEL EEVKARLQPY MAEAHELVGW
     NLEGLRQQLK PYTMDLMEQV ALRVQELQEQ LRVVGEDTKA QLLGGVDEAW ALLQGLQSRV
     VHHTGRFKEL FHPYAESLVS GIGRHVQELH RSVAPHAPAS PARLSRCVQV LSRKLTLKAK
     ALHARIQQNL DQLREELSRA FAGTGTEEGA GPDPQMLSEE VRQRLQAFRQ DTYLQIAAFT
     RAIDQETEEV QQQLAPPPPG HSAFAPEFQQ TDSGKVLSKL QARLDDLWED ITHSLHDQGH
     SHLGDP
//
